A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2019-06-04
Target enrollment:
Participant gender:
Summary
This study will look at the effect of adding the drug Palbociclib to CAD (Combined Androgen
Deprivation) therapy in patients with RB (Retinoblastoma Protein) positive hormone sensitive
prostate cancer.
The investigators hypothesize that the addition of Palbociclib to initial ADT (Androgen
Deprivation Therapy) in patients with newly metastatic RB-positive prostate cancer may
significantly increase the efficacy of ADT.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center
Collaborators:
City of Hope Comprehensive Cancer Center Johns Hopkins University Northwestern University Thomas Jefferson University University of Utah Vanderbilt-Ingram Cancer Center Washington University School of Medicine